HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Wedbush raised the firm’s price target on Arcus Biosciences (RCUS) to $35 from $33 and keeps an Outperform rating on the shares following third ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to opt in to ...

Arcus Biosciences ( ($RCUS) ) just unveiled an update. Arcus Biosciences, Inc. recently completed a public offering of its common stock, selling a ...

Dr. Markus will oversee Arcus’s clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies HAYWARD, Calif., January 21, ...

Arcus Biosciences presents a high-risk speculation with significant upcoming catalysts, despite recent stock declines and Gilead's exit from the ARC-10 trial. Gilead's continued investment and board ...

Arcus Biosciences (RCUS) just presented fresh data from its ARC-20 trial on casdatifan in metastatic renal cell carcinoma. The company also unveiled five new research programs in autoimmune and ...

Terry Rosen led Flexus Biosciences to a $1.25 billion acquisition by Bristol-Myers Squibb ($BMY) in roughly a year and a half. But now he and his team, including co ...

Wealth management technology provider Addepar acquired Arcus, a small tech startup that specializes in building out AI workflows, this week. While terms of the deal were not disclosed, Arcus’s ...